The relationship of thioredoxin-1 and cisplatin resistance: Its impact on ROS and oxidative metabolism in lung cancer cells

Molecular Cancer Therapeutics

Volumn 11, Issue 3, 2012, Pages 604-615

  Wangpaichitr, Medhi ^a   Sullivan, Elizabeth J ^c   Theodoropoulos, George ^a   Wu, Chunjing ^a   You, Min ^b   Feun, Lynn G ^b   Lampidis, Theodore J ^c   Kuo, Macus T ^d   Savaraj, Niramol ^a,b  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FUROIC ACID; 5 TETRADECYLOXY 2 FUROIC ACID; ACETYL COENZYME A CARBOXYLASE; ARGININE; ARGININOSUCCINATE SYNTHASE; CISPLATIN; ELESCLOMOL; FATTY ACID SYNTHASE; FUMARATE HYDRATASE; LACTIC ACID; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; THIOREDOXIN 1; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DEATH; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG CANCER; MITOCHONDRION; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ACETYL-COA CARBOXYLASE; ANTINEOPLASTIC AGENTS; ARGININOSUCCINATE SYNTHASE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FATTY ACID SYNTHETASE COMPLEX; FUMARATE HYDRATASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXYGEN CONSUMPTION; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; THIOREDOXINS;

EID: 84859400366     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0599     Document Type: Article

References (45)

1. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79. (Pubitemid 37487159)
2. Wangpaichitr M, Wu C, You M, Maher JC, Dinh V, Feun LG, et al. N1, N3-Dimethyl-N1,N3-bis(phenylcarbonothioyl) propanedihydrazide (elesclomol) selectively kills cisplatin resistant lung cancer cells through reactive oxygen species (ROS). Cancers (Basel) 2009;1:23-8.
3. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 1998;17:2596-606. (Pubitemid 28221195)
4. Sun Y, Rigas B. The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents. Cancer Res 2008;68:8269-77.
5. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 2005;39:696-703. (Pubitemid 41112110)
6. Rubartelli A, Bajetto A, Allavena G, Wollman E, Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem 1992;267:24161-4.
7. Rubartelli A, Bonifaci N, Sitia R. High rates of thioredoxin secretion correlate with growth arrest in hepatomacells.Cancer Res 1995;55:675-80.
8. Miyamoto S, Kawano H, Sakamoto T, Soejima H, Kajiwara I, Hokamaki J, et al. Increased plasma levels of thioredoxin in patients with coronary spastic angina. Antioxid Redox Signal 2004;6:75-80. (Pubitemid 38063977)
9. Powis G, Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 2007;7:392-7. (Pubitemid 47289261)
10. Wei SJ, Botero A, Hirota K, Bradbury CM, Markovina S, Laszlo A, et al. Thioredoxin nuclear translocation and interaction with redox factor-1 activates the activator protein-1 transcription factor in response to ionizing radiation. Cancer Res 2000;60:6688-95.
11. Ando K, Hirao S, Kabe Y, Ogura Y, Sato I, Yamaguchi Y, et al. A new APE1/Ref-1-dependent pathway leading to reduction of NF-kappaB and AP-1, and activation of their DNA-binding activity. Nucleic Acids Res 2008;36:4327-36.
12. Chutkow WA, Lee RT. Thioredoxin regulates adipogenesis through thioredoxin interacting protein (Txnip) protein stability. J Biol Chem 2011;286:29139-45.
13. Wangpaichitr M, Wu C, You M, Kuo MT, Feun L, Lampidis T, et al. Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 2008;591:124-7.
14. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4:25.
15. Savaraj N,WuC, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, et al. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol 2003;23:173-9.
16. Xu J, Tyan T, Cedrone E, Savaraj N, Wang N. Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection. Genes Chromosomes Cancer 1996;17:172-8. (Pubitemid 26418695)
17. Wangpaichitr M, Savaraj N, Maher J, Kurtoglu M, Lampidis TJ. Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther 2008;7:1506-13.
18. Feun L, You M, Wu CJ, Kuo MT, Wangpaichitr M, Spector S, et al. Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des 2008;14:1049-57. (Pubitemid 351982554)
19. Rubartelli A, Bajetto A, Bonifaci N, Di Blas E, Solito E, Sitia R. A novel way to get out of the cell. Cytotechnology 1993;11 Suppl 1:S37-40.
20. Huttemann M, Lee I, Pecinova A, Pecina P, Przyklenk K, Doan JW. Regulation of oxidative phosphorylation, the mitochondrial membrane potential, and their role in human disease. J Bioenerg Biomembr 2008;40:445-56.
21. McGilvery RW. Biochemistry: a functional approach. In: Dusseau J, editor. Chapter 11: The oxidation of coenzyme A. Philadelphia, PA: W.B. Saunders Company; 1970. p. 206-24.
22. Srere PA. An eclectic view of metabolic regulation: control of citrate synthase activity. Adv Enzyme Regul 1970;9:221-33.
23. Ratner S, AnslowWPJr, Petrack B. Biosynthesis of urea. VI. Enzymatic cleavage of argininosuccinic acid to arginine and fumaric acid. J Biol Chem 1953;204:115-25.
24. Halvorson DL, McCune SA. Inhibition of fatty acid synthesis in isolated adipocytes by 5-(tetradecyloxy)-2-furoic acid. Lipids 1984;19:851-6. (Pubitemid 15188497)
25. Nagai M, Vho N, Cu J, Wada Y. Elesclomol-Cu chelate selectively targetsmitochondria to induce oxidative stress [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; 2011. Abstract nr 2093.
26. Toogood PL. Mitochondrial drugs. Curr Opin Chem Biol 2008;12:457-63.
27. Berkenblit A, Eder JP Jr, Ryan DP, Seiden MV, Tatsuta N, Sherman ML, et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 2007;13:584-90. (Pubitemid 46225365)
28. O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, et al. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma. J Clin Oncol 2009;27:5452-8.
29. Nakamura H, De Rosa S, Roederer M, Anderson MT, Dubs JG, Yodoi J, et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 1996;8:603-11. (Pubitemid 26115876)
30. Nakamura H, Vaage J, Valen G, Padilla CA, Bjornstedt M, Holmgren A. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic Biol Med 1998;24:1176-86. (Pubitemid 28246731)
31. Sasada T, Nakamura H, Ueda S, Iwata S, Ueno M, Takabayashi A, et al. Secretion of thioredoxin enhances cellular resistance to cis- diamminedichloroplatinum (II). Antioxid Redox Signal 2000;2:695-705. (Pubitemid 32062321)
32. Sasada T, Nakamura H, Ueda S, Sato N, Kitaoka Y, Gon Y, et al. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med 1999;27:504-14. (Pubitemid 29408635)
33. Chen HH, Song IS, Hossain A, Choi MK, Yamane Y, Liang ZD, et al. Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol 2008;74:697-704.
34. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007;26:71-83. (Pubitemid 46452185)
35. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y,WuCJ, et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004;3:1543-9. (Pubitemid 40136709)
36. Welsh SJ, Bellamy WT, Briehl MM, Powis G. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis. Cancer Res 2002;62:5089-95. (Pubitemid 34984438)
37. Sullivan EJ, Kurtoglu M, Wangpaichitr M, Savaraj N, Lampidis T. Metabolic changes associated with acquired cisplatin resistance [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; 2011. Abstract nr 4087.
38. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT. Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther 2009;8:3223-33.
39. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007;120:897-905.
40. Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, et al. In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006;12:7126-31. (Pubitemid 44974513)
41. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002;62:5443-50.
42. Prieto V, Curley S, Ensor C, Holzberg F, Bomalaski J, Clak M. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation by arginine deiminase. Proc Am Soc Clin Oncol 22: 2003 (suppl; abstr 968).
43. Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG. Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 2010;10:405-12.
44. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005;23:7660-8. (Pubitemid 46291831)
45. Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, Yang Y, et al. Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 2009;29:4080-90.